Business Context and Reporting Period
Company: BIO-RAD LABORATORIES, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2008
Business Overview: Bio-Rad is a multinational manufacturer and distributor of Life Science research and Clinical Diagnostics products. The company operates two primary segments: Life Science and Clinical Diagnostics. Approximately 70% of sales are international, creating significant exposure to currency fluctuations.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2008 |
Three Months Ended June 30, 2007 |
Six Months Ended June 30, 2008 |
Six Months Ended June 30, 2007 |
|---|---|---|---|---|
| Net Sales | $452,361 | $339,114 | $874,558 | $661,622 |
| Gross Profit | $248,421 | $189,991 | $475,304 | $369,372 |
| Gross Margin % | 54.9% | 56.0% | 54.3% | 55.8% |
| Income from Operations | $59,708 | $35,686 | $109,447 | $74,536 |
| Net Income | $43,398 | $25,671 | $69,893 | $52,668 |
| Diluted EPS | $1.58 | $0.95 | $2.54 | $1.94 |
| Cash from Operations (6mo) | $66,911 (2008) vs $33,431 (2007) | |||
| Total Debt (Long-term + Current) | $455,367 (June 30, 2008) | |||
| Cash & Short-term Investments | $227,155 (June 30, 2008) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 33.4% in Q2 2008 and 32.2% for the six-month period compared to 2007. This growth was driven by the acquisition of DiaMed Holding AG (contributing ~$63.5M in Q2 and ~$126.2M in YTD) and a weakening U.S. dollar (contributing ~$27.3M in Q2 and ~$49.8M YTD).
- Profitability: Net income rose 69% in Q2 and 33% YTD. Diluted EPS increased from $0.95 to $1.58 in Q2.
- Margins: Consolidated gross margins declined slightly to 54.9% in Q2 (from 56.0% in 2007) and 54.3% YTD (from 55.8%). Excluding the DiaMed acquisition, margins were 56.1%. The decline is attributed to higher international manufacturing costs and the loss of royalty income from expired HIV patents in the Clinical Diagnostics segment.
- Expenses: SG&A as a percentage of sales decreased to 32.4% in Q2 (from 35.3% in 2007) due to sales volume leverage, though real spending increased. R&D expenses rose to 9.3% of sales in Q2, driven by Clinical Diagnostics development.
- Balance Sheet: Total assets increased to $2.1 billion. Inventory levels rose significantly to $382.7 million (from $321.0 million at year-end 2007) to support growth and the DiaMed integration.
Guidance, Outlook, and Risks
- Acquisition Activity: The company intends to offer to buy the remaining minority shares of DiaMed Holding AG in the second half of 2008, estimating a cash requirement of approximately $62 million. Management is also evaluating other potential acquisitions.
- Liquidity: Management believes cash flow from operations, combined with $227.2 million in cash/short-term investments and $195.3 million available under a revolving credit facility, is adequate to meet objectives.
- Market Conditions: The market for large capital equipment has slowed due to reduced spending by pharmaceutical and biotechnology customers. However, Bio-Rad is less impacted as reagents and apparatus comprise over 70% of sales.
- Legal Proceedings: A patent infringement case filed by Eppendorf AG regarding thermocycler devices was settled in August 2008. The company maintains that other ongoing legal matters are not expected to have a material adverse effect.
- Accounting Changes: The company is evaluating the impact of new FASB standards (SFAS 161, 160, 141R) effective in 2009, particularly regarding noncontrolling interests and business combinations.
Investor Verification Checklist
- DiaMed Integration: Verify the final purchase price allocation for DiaMed, as goodwill and intangible assets remain preliminary and subject to adjustment.
- Currency Sensitivity: Assess the impact of a strengthening U.S. dollar on future reported sales, given that 70% of revenue is international.
- Inventory Levels: Monitor the $61.7 million increase in inventory YTD to ensure it aligns with sales velocity and does not indicate obsolescence risks.
- Patent Expirations: Track the impact of expiring HIV patents on royalty revenue within the Clinical Diagnostics segment.
- Debt Covenants: Confirm continued compliance with leverage and interest coverage ratios under the Credit Agreement and Senior Subordinated Notes.